Matthew Weston
Stock Analyst at UBS
(4.25)
# 1,451
Out of 4,655 analysts
359
Total ratings
70.1%
Success rate
10.1%
Average return
Main Sectors:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: MRK Merck KGaA | Maintained: Buy | €150.00 | €136.40 | +9.97% | 37 | Aug 7, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €52.00 → €62.00 | €47.90 | +29.44% | 23 | Aug 5, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 332.00 | kr 293.50 | +13.12% | 28 | Aug 5, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,600p | 11,560p | +52.25% | 68 | Aug 4, 2026 | |
| EPA: SAN Sanofi | Maintained: Hold | €88.00 → €78.00 | €76.66 | +1.75% | 16 | Jul 31, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 200.00 | CHF 169.20 | +18.20% | 12 | Jul 24, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 116.00 | CHF 123.40 | -6.00% | 47 | Jul 22, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 1,940p | 1,852p | +4.78% | 18 | Jul 13, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Hold | €240.00 | €233.90 | +2.61% | 29 | Jul 13, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Hold | €220.00 | €181.60 | +21.15% | 16 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 376.00 | CHF 356.10 | +5.59% | 55 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $135.97 | n/a | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 750.00 | CHF 566.40 | n/a | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €95.00 → €72.00 | €161.50 | n/a | 3 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $310 | $44.88 | n/a | 3 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $151.97 | n/a | 1 | Jul 5, 2017 |
Merck KGaA
Aug 7, 2026
Maintained: Buy
Price Target: €150.00
Current: €136.40
Upside: +9.97%
Bayer Aktiengesellschaft
Aug 5, 2026
Maintained: Buy
Price Target: €52.00 → €62.00
Current: €47.90
Upside: +29.44%
Novo Nordisk A/S
Aug 5, 2026
Maintained: Hold
Price Target: kr 332.00
Current: kr 293.50
Upside: +13.12%
AstraZeneca PLC
Aug 4, 2026
Maintained: Buy
Price Target: 17,600p
Current: 11,560p
Upside: +52.25%
Sanofi
Jul 31, 2026
Maintained: Hold
Price Target: €88.00 → €78.00
Current: €76.66
Upside: +1.75%
Galderma Group AG
Jul 24, 2026
Maintained: Buy
Price Target: CHF 200.00
Current: CHF 169.20
Upside: +18.20%
Novartis AG
Jul 22, 2026
Maintained: Hold
Price Target: CHF 116.00
Current: CHF 123.40
Upside: -6.00%
GSK plc
Jul 13, 2026
Maintained: Hold
Price Target: 1,940p
Current: 1,852p
Upside: +4.78%
Sartorius Aktiengesellschaft
Jul 13, 2026
Maintained: Hold
Price Target: €240.00
Current: €233.90
Upside: +2.61%
Sartorius Stedim Biotech S.A.
Jul 13, 2026
Maintained: Hold
Price Target: €220.00
Current: €181.60
Upside: +21.15%
May 13, 2026
Maintained: Buy
Price Target: CHF 376.00
Current: CHF 356.10
Upside: +5.59%
Nov 1, 2024
Maintained: Buy
Price Target: $125
Current: $135.97
Upside: n/a
Jan 27, 2022
Maintained: Buy
Price Target: CHF 750.00
Current: CHF 566.40
Upside: n/a
Feb 11, 2020
Upgraded: Hold
Price Target: €95.00 → €72.00
Current: €161.50
Upside: n/a
Nov 2, 2018
Maintained: Hold
Price Target: $310
Current: $44.88
Upside: n/a
Jul 5, 2017
Downgraded: Sell
Price Target: n/a
Current: $151.97
Upside: n/a